Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of RZL-012 for reduction of submental fat
CTR20251086Phase 3Active
- Sponsor
- Raziel Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Tapencarium in submental fat, sponsored by Raziel Therapeutics. Started Jun 2025; status: active.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on CTR20251086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251086.